Literature DB >> 31885010

Circulating Levels of Pro-inflammatory Cytokines in Patients with Nonalcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis.

Abolghasem Hadinia1, Amir Hossein Doustimotlagh, Hamed Reza Goodarzi, Arash Arya, Mojtaba Jafarinia.   

Abstract

BACKGROUND: Pro-inflammatory cytokines are associated with systemic inflammatory responses.
OBJECTIVE: To investigate the levels of pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α) in patients with non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH) compared to healthy individuals.
METHODS: This case-control study was conducted on 30 patients with NAFL, 30 patients with NASH, and 30 healthy volunteers. The plasma level of IL-1β, IL-6, and TNF-α were determined by ELISA, and biochemical parameters were measured using colorimetric methods.
RESULTS: IL-1β and IL-6 levels were significantly higher in patients with NASH compared with NAFL and control group. However, TNF-α levels had no significant variations in NAFL and NASH patients compared to the control group (p=0.903 and p=0.960, respectively).
CONCLUSION: Results showed that the levels of ALT activity and pro-inflammatory cytokines were higher in patients with NASH compared to control and NAFL subjects; Therefore, steatosis and inflammation develop as a result of excessive pro-inflammatory factors in NASH.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31885010     DOI: 10.22034/IJI.2019.80284

Source DB:  PubMed          Journal:  Iran J Immunol        ISSN: 1735-1383            Impact factor:   1.603


  5 in total

1.  Berberine attenuates non-alcoholic steatohepatitis by regulating chemerin/CMKLR1 signalling pathway and Treg/Th17 ratio.

Authors:  Zengsheng Lu; Fengbin Lu; Liyan Wu; Beihui He; Zhiyun Chen; Maoxiang Yan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-06-10       Impact factor: 3.000

2.  Berberine Improves the Protective Effects of Metformin on Diabetic Nephropathy in db/db Mice through Trib1-dependent Inhibiting Inflammation.

Authors:  Bin Zhang; Xuelian Zhang; Chenyang Zhang; Guibo Sun; Xiaobo Sun
Journal:  Pharm Res       Date:  2021-11-12       Impact factor: 4.200

Review 3.  Controversies and Opportunities in the Use of Inflammatory Markers for Diagnosis or Risk Prediction in Fatty Liver Disease.

Authors:  Joeri Lambrecht; Frank Tacke
Journal:  Front Immunol       Date:  2021-02-09       Impact factor: 7.561

Review 4.  Innate and Adaptive Immunity Alterations in Metabolic Associated Fatty Liver Disease and Its Implication in COVID-19 Severity.

Authors:  Patricia Lamadrid; Marta Alonso-Peña; David San Segundo; Mayte Arias-Loste; Javier Crespo; Marcos Lopez-Hoyos
Journal:  Front Immunol       Date:  2021-03-30       Impact factor: 7.561

Review 5.  Physiopathology of Lifestyle Interventions in Non-Alcoholic Fatty Liver Disease (NAFLD).

Authors:  David Carneros; Guillermo López-Lluch; Matilde Bustos
Journal:  Nutrients       Date:  2020-11-12       Impact factor: 5.717

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.